“sarepta-therapeutics” Archives

in
Entry Author Date Location
Gene Editing Execs Talk Scientific, Regulatory Hurdles At BIO Panel 02/10/16 Boston
East Coast Biotech Roundup: Editas, Hep C, Akashi, Tarveda & More 01/29/16 Boston
Safety Issues Spur Foundation-Backed Akashi to Suspend Duchenne Trial 01/26/16 Boston
East Coast Biotech Roundup: Alkermes, Zafgen, Snowmaggedon & More 01/22/16 Boston
FDA Rejects BioMarin’s Duchenne Drug, Sarepta Up Next 01/14/16 San Francisco
At Duchenne Panel, Parents Plead With Experts, FDA Decision Looms 11/24/15 San Francisco
East Coast Biotech Roundup: Pfizergan, Zafgen, Codiak, Boston Pharma 11/23/15 Boston
WaVe, Voyager Get $170M Combined in Biotech’s Latest IPO Tests 11/11/15 Boston
East Coast Biotech Roundup: Zafgen, Decibel, Voyager & More 10/16/15 Boston
PTC Unveils Mixed Duchenne Results, But Plots an FDA Filing 10/15/15 New York
East Coast Biotech Roundup: Forum, Neon, Sarepta, Accelerator & More 10/02/15 Boston
East Coast Biotech Roundup: StartUp Health, Constellation, Highline & More 08/28/15 New York
WaVe Joins the Crossover Party With $66M Series B for RNA Drugs 08/18/15 Boston
East Coast Biotech Roundup: Editas, Checkmate, Ovid & More 08/14/15 Boston
Moving on From Sarepta, Krieg Lands at Cancer Startup Checkmate Pharma 08/12/15 Boston
RaNA CEO Renaud Turns To A Former Backer To Lead $55M Series B 07/23/15 Boston
East Coast Biotech Roundup: Vertex, Biogen, Sarepta, Juno, & More 07/06/15 Boston
BioMarin, Sarepta Update Positions In Race To Produce DMD Drug 06/29/15 San Francisco
East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More 05/22/15 Boston
After Shift to Duchenne and Cholesterol Drugs, Catabasis Files For IPO 05/14/15 Boston
East Coast Biotech Roundup: NY Bio Fund, Sarepta, ZappRx, & More 04/03/15 Boston
Garabedian’s Rocky Road at Sarepta Ends With Abrupt Resignation 04/01/15 Boston
After Unlikely Idenix Sale, Renaud Jumps to RaNA to Outfox Junk DNA 12/01/14 Boston
BioMarin Gambles $840M on Prosensa’s Duchenne Drug 11/24/14 San Francisco
East Coast Biotech Roundup: Regeneron, Sage, Tara, Alnylam, & More 11/14/14 Boston
East Coast Biotech Roundup: Sarepta, Aegerion, Syros, Aileron & More 10/31/14 Boston
More Drama for Sarepta as FDA Delays Duchenne Drug, Shares Tank 10/27/14 Boston
What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies 10/06/14 Seattle
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
Mapp’s Ebola Drug Shows Promise, But Making More Will Take Time 08/15/14 San Diego
Page 1 of 3 next page »